Key Drivers
- Strong Liquidity
- Modest Leverage
- Ongoing Losses
AIAI Summary
CSTL's upside now hinges on converting strong clinical evidence into sustained reimbursement and test adoption that unlocks profitability from its 77% gross margins, while investors should demand confirmation of durable cash conversion and margin discipline after the rally.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Modest Leverage
- •Ongoing Losses
CSTL has strong liquidity and modest leverage with improving quarterly losses and positive cash flow, but persistent unprofitability, cash depletion, and dilution risk warrant caution despite lower valuation multiples.
Price Behavior
Key Price Behavior Insights:
- •Strong monthly advance
- •Resistance rejection
- •Key support watch
CSTL remains bullish over the last month, but watch $33.40 support and $36.80 resistance after the sharp pullback from recent highs.
Sharp one-day pullback to $35.34 after reaching $36.80
Sentiment & News
Key News Insights:
- •Analyst upside
- •Clinical validation
- •Partnership expansion
Castle Biosciences' strong share momentum, projected analyst upside, and advancing diagnostic validation studies support a positive near-term outlook.
Continued clinical progress and favorable sentiment could strengthen CSTL's investment case
Similar Companies in Healthcare
Other companies in the same sector with AI ratings